HLS Therapeutics Inc experienced a notable uptick in its stock price, reflecting positive investor sentiment.
In yesterday's trading session, HLS Therapeutics Inc saw its stock price increase by 6.41%, closing at CA$4.15. This surge is a significant move for the company, which has been navigating a challenging market landscape.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$120.65M
52W high
$5.76
52W low
$3.56
1W change
+12.16%
Beta
0.83
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 76.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.33
+76.7% Upside
Current Price
C$4.15
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
43.4%
Annualized
90-Day Vol
32.4%
Annualized
Trend (90d)
-23.6%
Annualized drift
90d Mean
C$3.81
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$4.03 | C$3.47 – C$4.69 |
| 60 trading days | C$3.92 | C$3.17 – C$4.85 |
| 90 trading days | C$3.81 | C$2.94 – C$4.94 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The recent price increase could indicate growing confidence among investors in HLS Therapeutics' future prospects, particularly as the company continues to expand its product offerings in the Canadian market.
HLS Therapeutics Inc Market Cap Reaches CA$120.6 Million
With a market cap of CA$120.6 million, HLS Therapeutics is positioned in a niche sector that could see growth as it expands its cardiovascular portfolio.
Bull case
The rise in HLS Therapeutics' stock likely stems from its recent financial performance and strategic moves, like the successful launch of NILEMDO™ in Canada. This product addresses a significant need in the cardiovascular market, which may boost investor confidence.
Bear case
Despite the positive movement, investors should stay cautious. HLS Therapeutics hasn't yet established consistent profitability, as shown by its negative profit margin of -15.24%. This uncertainty means potential investors should carefully consider the company's financial health before jumping in.
Recent Performance Highlights
Advertisement
HLS Therapeutics Inc's stock price increased by 6.41% in yesterday's trading, closing at CA$4.15. This performance comes amidst the company's ongoing efforts to enhance its product lineup, particularly with the recent approval of NILEMDO™ in Canada.
Market Position and Future Outlook
With a market cap of CA$120.6 million, HLS Therapeutics remains a player to watch in the pharmaceutical sector. The company's focus on cardiovascular treatments positions it well for future growth, especially as healthcare needs evolve.
Investor Considerations
While the stock surge is encouraging, potential investors should consider HLS Therapeutics' current financial metrics, including its negative profit margin. Ongoing scrutiny of its financial health will be crucial as the company seeks to establish a more stable growth trajectory.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
